Sionna Therapeutics is trading 6.4% up at $7.32, with the rebound appearing most consistent with technical trading after the prior session’s sharp decline.
- On September 15, it fell 16.71% to $6.88.
- September 16 coverage identifies no fresh bullish company catalyst or explicit link to today’s rebound; biotech shares are broadly weaker.
- Latest disclosure: a 46% workforce reduction, restructuring, and plans for a 2027 Phase 2a trial of SION-451 plus SION-2222.